GLS1 overexpression may be a protective factor in OCCC. A, Kaplan-Meier curves of OCCC patients, divided by high (≥200, blue), intermediate (<200, ≥100, red) and low (<100, black) GLS1 expression levels. From left to right: PFS (12 vs. 19 vs. 22; P = 0.013; HR by 10 points increase = 0.93; 95% CI, 0.88–0.99), CSS (12 vs. 19 vs. 21; P = 0.014; HR by 10 points increase = 0.91; 95% CI, 0.85–0.98). OS (12 vs. 19 vs. 22; P = 0.021; HR by 10 points increase = 0.93; 95% CI, 0.87–0.99). Survival times are expressed in years. B, Kaplan–Meier curves of ARID1A⁺ patients, divided by high (≥200, blue), intermediate (<200, ≥100, red) and low (<100, black) GLS1 expression levels. From left to right: PFS (11 vs. 14 vs. 10, P = 0.023, HR by 10 points increase = 0.91; 95% CI, 0.84–0.99), CSS (11 vs. 14 vs. 10, P = 0.036, HR by 10 points increase = 0.88; 95% CI, 0.79–0.99), OS (11 vs. 14 vs. 10, P = 0.093; HR by 10 points increase = 0.93; 95% CI, 0.85–1.01). Survival times are expressed in years. C, Kaplan–Meier curves of ARID1A⁻ patients, divided by high (≥200, blue), intermediate (<200, ≥100, red) and low (<100, black) GLS1 expression levels. From left to right: PFS (1 vs. 4 vs. 12, P = 0.487; HR by 10 points increase = 0.96; 95% CI, 0.86–1.07), CSS (1 vs. 4 vs. 11; P = 0.647; HR by 10 points increase = 0.97; 95% CI, 0.87–1.09), OS (1 vs. 4 vs. 12; P = 0.511; HR = 0.97; 95% CI, 0.87–1.07). Survival times are expressed in years.